| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTD |
| Uniprot No | P43251-3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 44-545aa |
| 氨基酸序列 | AHTGEESVADHHEAEYYVAAVYEHPSILSLNPLALISRQEALELMNQNLD IYEQQVMTAAQKDVQIIVFPEDGIHGFNFTRTSIYPFLDFMPSPQVVRWN PCLEPHRFNDTEVLQRLSCMAIRGDMFLVANLGTKEPCHSSDPRCPKDGR YQFNTNVVFSNNGTLVDRYRKHNLYFEAAFDVPLKVDLITFDTPFAGRFG IFTCFDILFFDPAIRVLRDYKVKHVVYPTAWMNQLPLLAAIEIQKAFAVA FGINVLAANVHHPVLGMTGSGIHTPLESFWYHDMENPKSHLIIAQVAKNP VGLIGAENATGETDPSHSKFLKILSGDPYCEKDAQEVHCDEATKWNVNAP PTFHSEMMYDNFTLVPVWGKEGYLHVCSNGLCCYLLYERPTLSKELYALG VFDGLHTVHGTYYIQVCALVRCGGLGFDTCGQEITEATGIFEFHLWGNFS TSYIFPLFLTSGMTLEVPDQLGWENDHYFLRKSRLSSGLVTAALYGRLYE RDLEHHHHHH |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BTD(生物素酶)重组蛋白的3条模拟参考文献示例，供参考：
---
1. **文献名称**: "High-yield Production of Recombinant Human Biotinidase in Pichia pastoris for Therapeutic Use"
**作者**: Zhang Y, et al.
**摘要**: 研究利用毕赤酵母系统高效表达重组人生物素酶，通过发酵优化使蛋白产量提升5倍，并证实其酶活性与天然蛋白一致，为酶替代疗法奠定基础。
2. **文献名称**: "Functional Analysis of Mutant BTD Proteins via Recombinant Expression in HEK293 Cells"
**作者**: Müller S, et al.
**摘要**: 在HEK293细胞中表达多种BTD突变体重组蛋白，结合酶动力学实验揭示致病性突变对酶活性的影响，为遗传性生物素酶缺乏症提供分子机制解释。
3. **文献名称**: "Recombinant BTD-Fc Fusion Protein Prolongs Serum Half-life in Murine Models"
**作者**: Chen L, et al.
**摘要**: 构建BTD与IgG Fc片段的重组融合蛋白，证明其在小鼠体内半衰期延长3倍，且保持酶活性，显著改善疾病模型的代谢指标。
---
**注**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Google Scholar)检索具体论文。若需真实文献，建议使用关键词“recombinant biotinidase”或“BTD protein expression”进行查找。
**Background of BTD Recombinant Proteins**
BTD (Biotinylated Target Domain) recombinant proteins are engineered biomolecules designed for applications in biomedical research, diagnostics, and therapeutic development. These proteins are generated through recombinant DNA technology, where specific target domains—often functional or binding regions of larger proteins—are fused with a biotinylation tag. This tag enables efficient conjugation with streptavidin or avidin, facilitating applications in affinity-based assays, protein localization studies, and targeted drug delivery systems.
The development of BTD recombinant proteins stems from the need for high-specificity tools in proteomics and molecular interaction studies. By incorporating a biotinylation sequence (e.g., AviTag) during expression, these proteins achieve site-specific biotinylation, ensuring consistent orientation and functionality when immobilized on surfaces or conjugated with probes. Common host systems for production include *E. coli*, yeast, or mammalian cells, chosen based on the protein’s complexity and post-translational modification requirements.
BTD recombinant proteins are widely used in ELISA, pull-down assays, and biosensor technologies due to their stable binding to streptavidin-coated platforms. In therapeutics, they serve as targeting moieties in antibody-drug conjugates (ADCs) or bispecific antibodies, leveraging biotin-streptavidin interactions for modular drug assembly. Challenges in their development include optimizing expression yields, minimizing aggregation, and maintaining biological activity post-modification.
Recent advancements focus on improving biotinylation efficiency and expanding applications in nanotechnology and personalized medicine. For instance, BTD-functionalized nanoparticles are explored for precise drug delivery, while CRISPR-based editing tools utilize biotinylated Cas9 variants for enhanced genomic targeting. As the demand for customizable, multifunctional proteins grows, BTD recombinant systems remain pivotal in bridging molecular engineering with real-world biomedical solutions.
×
